What Zidoval Treats: Main Uses and Benefits

Zidoval (metronidazole vaginal gel) is primarily used to address the symptoms of Bacterial Vaginosis (BV), a condition where the natural bacterial balance in the vagina is affected.

Symptomatic Relief in Acute Episodes

Zidoval is commonly used to help with the challenging symptom clusters that often appear suddenly or intensify during a BV episode. This includes addressing abnormal, often profuse discharge and the characteristic unpleasant, fishy odor. The medication is applied across therapeutic domains where additional symptomatic support is needed, providing support that helps ease the overall symptom load and contributes to improved day-to-day comfort during symptomatic periods.

Management of Recurrent and Persistent Conditions

The medication is relevant in conditions characterized by periods of heightened symptoms, including cases of recurrent or episodic BV. It is commonly used when supportive symptom management is appropriate in addressing persistent manifestations. When applied appropriately, it helps maintain a sense of stability when symptoms are more noticeable, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Symptoms of Bacterial Vaginosis

Regulatory References

1. US DailyMed drug labeling information

Zidoval (metronidazole vaginal gel) is approved for use in specific populations as defined by regulatory bodies, which also impose strict restrictions and contraindications based on patient history, age, and existing medical conditions.

Contraindicated Populations (Must Not Use)

Classification	Basis for Exclusion (Official Regulatory)
Hypersensitivity	Prior history of allergy to metronidazole, other nitroimidazole derivatives, or any excipient in the formulation (e.g., parabens).
Recent Drug Use	Has taken Disulfiram (Antabuse) within the last two weeks.
Alcohol Consumption	Consumption of alcohol during treatment and for at least 24 hours (up to 48 hours) after the final dose.

Eligibility and Age Restrictions

Approved Groups: Use is established for adult women. The US FDA authorizes use in adolescent females 12 years of age and older. Older adults generally have no specific limitations, though clinical data is limited in this population.

Restricted Groups: Safety and effectiveness are not established for female patients under 12 years of age. In some regions (e.g., EMA/SmPC), the medicine is not recommended for adolescents under 18 years.

Condition-Based Cautions

Use requires caution or is otherwise restricted for patients with certain pre-existing conditions as described in the official label:

• Severe Hepatic Disease: Administered cautiously due to slower metabolism and potential for drug accumulation.
• CNS Diseases: Use with caution; prompt discontinuation is required if abnormal neurological signs (e.g., seizures) appear.
• Blood Dyscrasia: Used with care, as metronidazole is a nitroimidazole.
• Cockayne Syndrome: Use is generally avoided unless no alternative exists, with mandatory liver function testing required due to risk of severe hepatotoxicity.

Pregnancy and Lactation Status

• Pregnancy: Classified as Category B by the US FDA. Use is generally restricted to when it is clearly needed. Use during the first trimester is a formal contraindication in some national prescribing information.
• Lactation: Metronidazole is excreted in human milk. Nursing mothers should consider discontinuing milk feeding or pump and discard breastmilk during treatment and for 24 to 48 hours after the last dose.

Interactions with other medicines and products

Regulatory documentation defines specific restrictions and necessary considerations when using metronidazole topical gel concurrently with certain substances or conditions. This information pertains strictly to officially documented interaction patterns.

Contraindicated Combinations and Timing Rules

Co-administration with Disulfiram is formally contraindicated if the substance has been taken within the last two weeks, a restriction noted due to the risk of psychotic reactions associated with oral metronidazole. Consumption of Alcohol (Ethanol) and products containing Propylene Glycol is also contraindicated during therapy and for a minimum of 24 hours after treatment completion, based on the potential for a disulfiram-like reaction.

---

Pharmacokinetic and Pharmacodynamic Interactions

Specific interactions are documented that affect drug levels or clinical outcomes. The use of the gel requires consideration when co-administered with Warfarin and other Coumarin Anticoagulants, as oral metronidazole is reported to potentiate the anticoagulant effect and prolong prothrombin time. Substances such as Lithium and Cimetidine are associated with an officially documented increase in metronidazole plasma concentrations through reduced clearance. Furthermore, metronidazole can interfere with certain enzymatic laboratory determinations of serum chemistry values, potentially yielding falsely reduced results.

---

Population-Specific Considerations

In patients with severe hepatic disease, official labeling notes that metronidazole clearance is reduced, which results in the accumulation of the drug and its metabolites in the plasma.

Selective Activation: Targeting Anaerobic Metabolism

The fundamental action of Zidoval is based on its role as a prodrug that must be activated by the low-oxygen internal environment characteristic of susceptible anaerobic pathogens. Specific microbial nitroreductase enzymes reduce the drug's nitro group ( NO2), converting the inert substance into a highly reactive, cytotoxic metabolite. This mechanism of selective toxicity ensures the cytotoxic effects are concentrated exclusively within the targeted organisms, which results in the targeted microbial cell death.

---

Irreversible DNA Damage and Bactericidal Effect

The unstable, activated metabolites immediately generate nitroso radicals that rapidly attack the pathogen's DNA. By binding covalently and causing strand breakage, this mechanism irreversibly disrupts the core processes of replication and nucleic acid synthesis. This widespread cellular destruction results in a rapid bactericidal effect, which is the direct physiological change resulting in the irreversible destruction of the pathogenic microbe population.

---

Mechanistic Constraints

The drug's activity is physiologically constrained by environmental factors, as the activating reaction is highly sensitive to oxygen. Oxygen actively competes with the drug for the necessary electrons, a process that inhibits the activation and restricts the cytotoxic metabolite formation in aerobic organisms. This limitation defines the range of environments where the cytotoxic mechanism can operate.

How to Use Zidoval (Metronidazole) Vaginal Gel

Zidoval is a prescription medication formulated as a 0.75% vaginal gel containing metronidazole, intended strictly for intravaginal administration. Usage instructions define the route, dosage, frequency, and course duration, and must be followed as prescribed.

Official Administration Guidelines

The standard administration parameters are as follows:

Guideline Entity	Official Instruction
Route & Form	0.75% Gel, Intravaginal use only.
Standard Dose	One applicator-full of gel (approximately 5g, delivering 37.5 mg metronidazole).
Frequency	Once daily, typically administered at bedtime.
Course Duration	5 consecutive days.

Administration Procedures and Restrictions

Procedural Steps: The gel is applied using the single-use applicator provided. The applicator must be filled from the tube to the specified mark or until the plunger stops to ensure the correct dose is loaded. The filled applicator is then gently inserted into the vagina and the plunger is pushed to release the entire dose. The used applicator should be discarded.

Special Conditions: The full course of five days must be completed, even if symptoms appear to resolve earlier. Treatment should not be used during menstruation (menses). If a dose is missed, it should be applied as soon as possible, but if it is almost time for the next dose, the missed dose should be skipped.

Population Rules: Zidoval is not recommended for use in children and adolescents under 18 years of age, as safety and effectiveness in this population have not been established.

Research Evidence / Overview of Studies for Zidoval (Metronidazole Vaginal Gel)

Evidence for Use in Bacterial Vaginosis (BV)

Zidoval (metronidazole vaginal gel) was evaluated in research exploring bacterial vaginosis (BV), a condition characterized by fluctuating or episodic manifestations. The main body of research was evaluated in randomized controlled trials (RCTs). These types of studies are designed to reduce bias by comparing the gel formulation against an inactive gel (placebo) or against other known treatments was observed in trials for the condition. The research examined adult women diagnosed with BV in studies observing responses over defined time intervals.

Researchers primarily evaluated outcomes related to physical discomfort and microbiological changes. These included assessing the change in key BV clinical signs (such as abnormal discharge and odor) and changes in the types of bacteria present in the vaginal environment. The studies report how symptoms evolved in the observed populations, and these findings describe patterns observed in the studies over the short term. The evidence contributes to understanding symptom patterns during periods of increased symptom activity.

Outcomes Measured in Clinical Trials: Change and Endpoint Achievement

The trials monitored specific measurements to determine whether a predefined study endpoint was met. One key measure was evaluated in the research exploring short-term symptom changes, focusing on the achievement of clinical change. Another main measure was the achievement of a microbiological change, which means the microscopic assessment of the vaginal flora shifted away from the pattern seen in BV.

Long-Term Studies and Recurrence Patterns

Research has explored the question of what happens after the initial follow-up period, as BV is a condition often presenting with cycles of stability and flare-ups. Follow-up durations were limited in many of the core efficacy trials. Data show patterns related to recurrence after the initial treatment interval, which was observed in some studies regardless of the specific treatment used. This highlights a key limitation documented in research into this condition and indicates that long-term outcomes are not fully established based on the current body of work.

Evidence in Specific Patient Populations

Data for certain groups remain insufficient, particularly for populations who fall outside the core study criteria. Studies explored the use of metronidazole in certain patient groups, such as adolescents or pregnancy-related populations, but data for the Zidoval gel formulation remain uncertain in these subgroups.

Key Studies & References Metronidazole Vaginal Gel, 0.75% (Prescribing Information / DailyMed) (Informing indication, measured outcomes, and special population data gaps)

Common questions about Zidoval (FAQ)

Q: Is Zidoval the same thing as the metronidazole oral tablet?

According to official regulatory information, Zidoval vaginal gel is not identical to the metronidazole oral tablet. While both contain the same active ingredient, the key difference is in how the drug enters the body. Because the gel is applied topically, the amount of metronidazole absorbed systemically (into the bloodstream) is significantly lower than after taking an oral dose.

Q: Why is Zidoval used specifically for bacterial vaginosis (BV)?

Zidoval vaginal gel is specifically indicated in regulatory documents for the treatment of symptomatic bacterial vaginosis. This is because the active ingredient, metronidazole, is effective against the specific type of anaerobic bacteria that are associated with this condition.

Q: Is Zidoval safe for people with a history of liver problems?

Official guidance advises caution when using metronidazole in patients who have a history of liver disease. This is because the liver is involved in processing the drug. Official information states that caution is necessary, and all relevant medical history is typically reviewed by a prescribing professional.

Q: How often are allergic reactions reported with Zidoval gel?

The official product information lists a known hypersensitivity (severe allergy) to metronidazole, other related drugs, or certain ingredients as a strict contraindication. The medication is contraindicated for those with a known allergy. Any severe reaction is a circumstance that necessitates immediate consultation with a healthcare professional.

Q: How long after finishing Zidoval can the original BV symptoms potentially return?

Research studies have explored the question of recurrence after treatment for bacterial vaginosis. Clinical trials evaluating metronidazole gel reported a recurrence rate of approximately 15% one month after the end of the full treatment course.

Q: Is there anything that makes Zidoval less effective?

Regulatory warnings indicate that not completing the full prescribed course of treatment is not recommended. Stopping the course too early or using the medication during menstruation may result in a return of the infection.

Q: How does Zidoval compare to oral metronidazole for BV success rates?

Clinical trial results indicate that metronidazole gel treatment results in a high clinical cure rate. The observed recurrence rate for the gel was similar to the recurrence rates reported in studies of the oral form of metronidazole.

Q: What is Zidoval's official risk classification for safe use?

Zidoval is classified as a Prescription Only Medicine (POM) in various regulatory regions. This status is required because the product contains the antibiotic metronidazole, ensuring appropriate use, correct diagnosis, and helping manage the risk of antimicrobial resistance.

Q: Is Zidoval used to treat infections in men?

Zidoval vaginal gel is specifically approved and formulated for the treatment of bacterial vaginosis in adult women. The regulatory documents do not mention its use for infections in men.

Q: Does Zidoval affect fertility or ability to become pregnant?

Official guidance advises caution when prescribing to pregnant or lactating women, as metronidazole can cross the placenta and is excreted in breast milk. There are no formal studies stating a direct effect on female fertility, but untreated bacterial vaginosis can be a risk factor for pelvic inflammatory disease.

Q: Does Zidoval treat yeast infections or thrush too?

No, Zidoval is only for bacterial infections. Official regulatory labeling notes that the use of Zidoval may cause a new or unrecognised candidiasis (thrush) to present more prominent symptoms, which may then require separate antifungal treatment.

Q: How long does metronidazole from Zidoval stay in the body?

Based on studies of the drug's absorption, the mean half-life (the time taken for half the drug to be eliminated) in the body is approximately 9.65 hours after vaginal application.

Q: Can I use vaginal deodorants or douches while I am using Zidoval?

Official regulatory information advises against the use of douches, tampons, or other vaginal products while using this medication. Regulatory information advises against sexual intercourse while using the medication.

Q: How fast does Zidoval typically start to work for BV symptoms?

While the full course of treatment must be completed to achieve a cure, clinical trial data shows that endpoints for cure are typically met by Day 7. General clinical experience suggests that users may begin to feel relief from symptoms within two or three days.

Q: Does Zidoval interact with oral contraceptive pills (birth control)?

Due to the low level of systemic absorption of the gel, major interaction with oral contraceptive pills is considered unlikely by regulatory authorities. However, it is considered best practice that all medications are reviewed by a prescribing professional.

Q: Is it safe to take paracetamol (acetaminophen) while using Zidoval?

Due to the low level of systemic absorption of the gel, a significant interaction with paracetamol (acetaminophen) is not generally expected. It is considered best practice that all new medications are reviewed by a pharmacist or prescribing professional.

Q: What is the risk of developing a serious condition like peripheral neuropathy from Zidoval?

Although rare, the possibility of peripheral neuropathy (a condition involving nerve damage that can cause symptoms like tingling or numbness) has been reported with topical metronidazole use in post-marketing experience. If these symptoms are experienced, the official guidance is to consult promptly with a healthcare professional.

Q: What precautions are necessary for Zidoval use in people with blood disorders?

Regulatory warnings state that metronidazole is part of the nitroimidazole drug class and should be used with care in patients who have evidence of, or a history of, blood dyscrasia (abnormalities in the blood components).

Q: Is there a risk of developing a new infection while using Zidoval?

Regulatory documents warn that the use of Zidoval may result in a new vaginal infection. Specifically, candidiasis (thrush) is noted as a possibility that may require separate treatment with an antifungal agent.

Q: What official guidance exists for Zidoval use in people with kidney problems?

Regulatory guidance notes that metronidazole itself does not accumulate in the body for patients with renal failure. However, the drug's metabolites (byproducts) are retained, and both metronidazole and its metabolites are removed by hemodialysis.

Q: What research exists regarding Zidoval's ability to help restore the vaginal pH balance?

Zidoval is used to treat bacterial vaginosis, which is characterized by an elevated vaginal pH. The therapeutic goal is to eliminate the pathogenic bacteria, which allows the natural vaginal environment, including the pH level, to return to its normal acidic range.

Q: Does Zidoval affect the risk or transmission of STIs/STDs?

Official regulatory documents state that Zidoval is only indicated for the treatment of bacterial vaginosis. It is not effective against and does not treat common sexually transmitted infections (STIs/STDs) such as Trichomonas vaginalis or Neisseria gonorrhoeae.

Storage and Handling Requirements

Zidoval 7.5 mg/g vaginal gel must be stored according to regulatory requirements to preserve product stability. The product should not be stored above 25 C and must be kept from freezing. Storage should be away from excessive moisture and direct light. The medication must remain in its original container, tightly closed.

Child Protection and Safety

It is a mandatory safety requirement that this medicine be kept out of the sight and reach of children at all times.

Official Disposal Rules

Disposal of unused or expired Zidoval gel and any waste material must be done in accordance with local regulations and pharmacy instructions. The medication should not be thrown away via wastewater or household waste. Used disposable applicators, however, should be safely discarded in the trash immediately after use.